Journal
BIOMOLECULES
Volume 13, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biom13020395
Keywords
heart failure; biomarkers; heart failure with preserved ejection fraction; HFpEF; HCM; hypertrophic cardiomyopathy; FKBPL; plasma; angiotensin; AD-01
Categories
Ask authors/readers for more resources
Heart failure (HF) is a major cause of hospitalizations worldwide, with a low survival rate within 5 years after diagnosis. The role of FKBPL in HFpEF pathogenesis and as a biomarker was investigated in in vitro cardiac hypertrophy models and human plasma samples. The results suggest that FKBPL may have therapeutic potential in HFpEF but is unable to differentiate between different forms of HFpEF.
Heart failure (HF) is the leading cause of hospitalisations worldwide, with only 35% of patients surviving the first 5 years after diagnosis. The pathogenesis of HF with preserved ejection fraction (HFpEF) is still unclear, impeding the implementation of effective treatments. FK506-binding protein like (FKBPL) and its therapeutic peptide mimetic, AD-01, are critical mediators of angiogenesis and inflammation. Thus, in this study, we investigated-for the first time-FKBPL's role in the pathogenesis and as a biomarker of HFpEF. In vitro models of cardiac hypertrophy following exposure to a hypertensive stimulus, angiotensin-II (Ang-II, 100 nM), and/or AD-01 (100 nM), for 24 and 48 h were employed as well as human plasma samples from people with different forms of HFpEF and controls. Whilst the FKBPL peptide mimetic, AD-01, induced cardiomyocyte hypertrophy in a similar manner to Ang-II (p < 0.0001), when AD-01 and Ang-II were combined together, this process was abrogated (p < 0.01-0.0001). This mechanism appears to involve a negative feedback loop related to FKBPL (p < 0.05). In human plasma samples, FKBPL concentration was increased in HFpEF compared to controls (p < 0.01); however, similar to NT-proBNP and Gal-3, it was unable to stratify between different forms of HFpEF: acute HFpEF, chronic HFpEF and hypertrophic cardiomyopathy (HCM). FKBPL may be explored for its biomarker and therapeutic target potential in HFpEF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available